CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Subscription Receivable	Receivable from Shareholder	Accumulated Deficit	Previously Reported	Previously Reported Common Stock	Previously Reported Additional Paid-In Capital	Previously Reported Subscription Receivable	Previously Reported Receivable from Shareholder	Previously Reported Accumulated Deficit	Revision of Prior Period, Adjustment	Revision of Prior Period, Adjustment Common Stock	Revision of Prior Period, Adjustment Additional Paid-In Capital	Revision of Prior Period, Adjustment Subscription Receivable	Revision of Prior Period, Adjustment Receivable from Shareholder	Revision of Prior Period, Adjustment Accumulated Deficit
Balance as of beginning of period (in shares) at Dec. 31, 2022	0						32,575,043						(32,575,043)
Balance as of beginning of period at Dec. 31, 2022	$ 0						$ 33						$ (33)
Balance as of end of period (in shares) at Sep. 30, 2023	0
Balance as of end of period at Sep. 30, 2023	$ 0
Balance as of beginning of period (in shares) at Dec. 31, 2022		13,303,795						0						13,303,795
Beginning balance at Dec. 31, 2022	1,563	$ 1	$ 80,738	$ 0	$ 0	$ (79,176)	$ 1,563	$ 0	$ 80,706	$ 0	$ 0	$ (79,176)	$ 0	$ 1	$ 32	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,207		3,207
Conversion of liability classified warrants to equity pursuant to sequencing policy	0
Exercise of common stock options (in shares)		12,867
Exercise of common stock options	12		12
Reverse recapitalization transactions, net (in shares)		8,572,314,000
Reverse recapitalization transactions, net	3,928	$ 1	36,842	(32,915)
Net income (loss)	(49,348)					(49,348)
Balance as of ending of period (in shares) at Sep. 30, 2023		21,888,976
Ending balance at Sep. 30, 2023	$ (40,638)	$ 2	120,799	(32,915)	0	(128,524)
Balance as of beginning of period (in shares) at Jun. 30, 2023	0						32,606,548						(32,606,548)
Balance as of beginning of period at Jun. 30, 2023	$ 0						$ 33						$ (33)
Balance as of end of period (in shares) at Sep. 30, 2023	0
Balance as of end of period at Sep. 30, 2023	$ 0
Balance as of beginning of period (in shares) at Jun. 30, 2023		13,316,662						0						13,316,662
Beginning balance at Jun. 30, 2023	(12,356)	$ 1	82,990	0	0	(95,347)	$ (12,356)	$ 0	$ 82,958	$ 0	$ 0	$ (95,347)	$ 0	$ 1	$ 32	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	967		967
Reverse recapitalization transactions, net (in shares)		8,572,314
Reverse recapitalization transactions, net	3,928	$ 1	36,842	(32,915)
Net income (loss)	(33,177)					(33,177)
Balance as of ending of period (in shares) at Sep. 30, 2023		21,888,976
Ending balance at Sep. 30, 2023	$ (40,638)	$ 2	120,799	(32,915)	0	(128,524)
Balance as of beginning of period (in shares) at Dec. 31, 2023	0
Balance as of beginning of period at Dec. 31, 2023	$ 0
Balance as of end of period (in shares) at Sep. 30, 2024	0
Balance as of end of period at Sep. 30, 2024	$ 0
Balance as of beginning of period (in shares) at Dec. 31, 2023		21,888,976
Beginning balance at Dec. 31, 2023	(58,693)	$ 2	121,727	(17,792)	(500)	(162,130)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	3,307		3,307
Issuance of common stock in connection with financial instrument transactions (in shares)		13,660,000
Issuance of common stock in connection with financial instrument transactions	4,146	$ 2	4,144
Issuance of common stock (in shares)		166,667
Issuance of common stock	100		100
Conversion of liability classified warrants to equity pursuant to sequencing policy	297		297
Forward purchase contract subscription	0		624	(624)
Amendment of forward purchase contracts	13,153			13,153
Settlement of forward purchase contracts	5,012			5,012
Settlement of receivable from shareholder	$ 500				500
Exercise of common stock options (in shares)	0
Net income (loss)	$ (14,872)					(14,872)
Balance as of ending of period (in shares) at Sep. 30, 2024		35,715,643
Ending balance at Sep. 30, 2024	$ (47,050)	$ 4	130,199	(251)	0	(177,002)
Balance as of beginning of period (in shares) at Jun. 30, 2024	0
Balance as of beginning of period at Jun. 30, 2024	$ 0
Balance as of end of period (in shares) at Sep. 30, 2024	0
Balance as of end of period at Sep. 30, 2024	$ 0
Balance as of beginning of period (in shares) at Jun. 30, 2024		25,771,132
Beginning balance at Jun. 30, 2024	(69,717)	$ 3	124,586	(10,706)	0	(183,600)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	1,092		1,092
Issuance of common stock in connection with financial instrument transactions (in shares)		9,777,844
Issuance of common stock in connection with financial instrument transactions	4,114	$ 1	4,113
Issuance of common stock (in shares)		166,667
Issuance of common stock	100		100
Forward purchase contract subscription	0		308	(308)
Amendment of forward purchase contracts	10,389			10,389
Settlement of forward purchase contracts	374			374
Net income (loss)	6,598					6,598
Balance as of ending of period (in shares) at Sep. 30, 2024		35,715,643
Ending balance at Sep. 30, 2024	$ (47,050)	$ 4	$ 130,199	$ (251)	$ 0	$ (177,002)